Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Advanced Electron Microscopy Reveals Fine Structure of Active Signaling Complexes

By BiotechDaily International staff writers
Posted on 07 Jul 2014
Image: A structural model of the beta2 adrenergic receptor-arrestin signaling complex as deduced by electron microscopy, cross-linking, and mass spectrometry (Photo courtesy of Duke University).
Image: A structural model of the beta2 adrenergic receptor-arrestin signaling complex as deduced by electron microscopy, cross-linking, and mass spectrometry (Photo courtesy of Duke University).
A team of molecular biologists used advanced electron microscopy and mass spectroscopy techniques to determine the structure of the functional human beta2AR (beta2 adrenergic receptor)-beta-arrestin-1 signaling complex.

Members of arrestin/beta-arrestin protein family are thought to participate in agonist-mediated desensitization of G-protein-coupled receptors (GPCRs) and cause specific dampening of cellular responses to stimuli such as hormones, neurotransmitters, or sensory signals.

While a recent barrage of structural data on a number of GPCRs including the beta2AR–G-protein complex has provided novel insights into the structural basis of receptor activation, information has been lacking on the recruitment of beta-arrestins to activated GPCRs, primarily owing to challenges in obtaining stable receptor–beta-arrestin complexes for structural studies.

Investigators at Duke University (Durham, NC, USA) and colleagues at the University of Michigan (Ann Arbor, USA) and Stanford University (Palo Alto, CA, USA) devised a strategy for forming and purifying a functional human beta2AR–beta-arrestin-1 complex that allowed them to visualize its architecture by single-particle negative-stain electron microscopy and to characterize the interactions between beta2AR and beta-arrestin 1 using hydrogen–deuterium exchange mass spectrometry (HDX-MS) and chemical cross linking.

Electron microscopy two-dimensional averages and three-dimensional reconstructions revealed bimodal binding of beta-arrestin 1 to the beta2AR, involving two separate sets of interactions, one with the phosphorylated carboxyl terminus of the receptor and the other with its seven-transmembrane core. Areas of reduced HDX together with identification of cross linked residues suggested engagement of the finger loop of beta-arrestin 1 with the seven-transmembrane core of the receptor.

A molecular model of the beta2AR–beta-arrestin signaling complex was made by docking activated beta-arrestin and beta2AR crystal structures into the electron microscopy map densities with constraints provided by HDX-MS and cross linking. This model, which was published in the June 22, 2014, edition of the journal Nature, provided valuable insights into the overall architecture of a receptor–arrestin complex.

“Arrestin’s primary role is to put the cap on GPCR signaling. Elucidating the structure of this complex is crucial for understanding how the receptors are desensitized in order to prevent aberrant signaling,” said co-senior author Dr. Georgios Skiniotis, professor of life sciences at the University of Michigan.

Related Links:

Duke University
University of Michigan
Stanford University



Channels

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.